Patent US5776783A successfully refreshed from Google Patents.
US5776783A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of monitoring therapeutic agent consumption
Assignee: PROGRESSION Ltd
•
Filing: 1996-09-17
•
Granted: 1998-07-07
•
Expires: 2016-09-17
Abstract
Abstract Quantitative compliance markers and associated methods for monitoring patient compliance with medication prescriptions associated with compliance markers have been found to eliminate the need for specific quantitative relationships for each new drug tested. Such compliance markers and methods for monitoring patient compliance utilize pharmacologically inert substances, namely the weak acids benzodiazepines, or non-metabolizable substances in association with an underlying drug at a measurable dosage, so as to correlate compliance marker concentration with underlying medication concentration to determine amount of actual medication ingested.
Inventors
- 👤 Michael Kell
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 17:33
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/483; G01N33/487; G01N33/493; G01N33/50; G01N33/94; G01N33/948; Y; Y10; Y10S; Y10S436/00; Y10S436/807; Y10S436/808; Y10S436/901; Y10T; Y10T436/00; Y10T436/17; Y10T436/173845
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
157 words
A method of monitoring compliance of a patient who has been placed on a medication maintenance program with a prescribed medication dosage, and with the method comprising the steps of: (a) physically associating a compliance marker with a prescribed medication dosage prior to ingestion, (b) obtaining a sample of the patient's urine, (c) measuring the concentration of the compliance marker and its metabolites in the urine and the urine specific gravity, (d) calculating a normalized urine compliance marker and its metabolite concentration as a function of the measured compliance marker and its metabolite concentration in the urine and the urine specific gravity adjusted to account for the difference between the urine measured specific gravity and a preselected reference urine specific gravity, (e) comparing the normalized urine compliance marker and its metabolite concentration with an expected normalized urine compliance marker and its metabolite concentration for the amount of compliance marker prescribed, as an indication of compliance or non-compliance.
Claim 2
Independent Claim
157 words
A method of monitoring compliance of a patient who has been placed on a medication maintenance program with a prescribed medication dosage, and with the method comprising the steps of: (a) physically associating a compliance marker with a prescribed medication dosage prior to ingestion, (b) obtaining a sample of the patient's urine, (c) measuring the concentration of the compliance marker and its metabolites in the urine and the urine specific gravity, (d) calculating a normalized urine compliance marker and its metabolite concentration as a function of the measured compliance marker and its metabolite concentration in the urine and the urine specific gravity adjusted to account for the difference between the urine measured specific gravity and a preselected reference urine specific gravity, (e) comparing the normalized urine compliance marker and its metabolite concentration with an expected normalized urine compliance marker and its metabolite concentration for the amount of compliance marker prescribed, as an indication of compliance or non-compliance.
Claim 3
Dependent Claim
50 words
The method of claim 1 further including the step: (f) calculating the amount of prescribed medication actually ingested by multiplying the prescribed medication dose with the calculated normalized urine compliance marker and its metabolite concentration, and dividing the product by the expected normalized urine compliance marker and its metabolite concentration.
Claim 4
Independent Claim
157 words
A method of monitoring compliance of a patient who has been placed on a medication maintenance program with a prescribed medication dosage and having a compliance marker physically associated with the medication at a predetermined dosage, and with the method comprising the steps of: (a) obtaining a sample of the patient's urine, (b) measuring the concentration of the compliance marker and its metabolites in the urine and the urine specific gravity, (c) calculating a normalized urine compliance marker and its metabolite concentration as a function of the measured compliance marker and its metabolite concentration in the urine and the urine specific gravity adjusted to account for the difference between the urine measured specific gravity and a preselected reference urine specific gravity, (d) comparing the normalized urine compliance marker and its metabolite concentration with an expected normalized urine compliance marker and its metabolite concentration for the amount of compliance marker prescribed, as an indication of compliance or non-compliance.
Claim 5
Independent Claim
157 words
A method of monitoring compliance of a patient who has been placed on a medication maintenance program with a prescribed medication dosage and having a compliance marker physically associated with the medication at a predetermined dosage, and with the method comprising the steps of: (a) obtaining a sample of the patient's urine, (b) measuring the concentration of the compliance marker and its metabolites in the urine and the urine specific gravity, (c) calculating a normalized urine compliance marker and its metabolite concentration as a function of the measured compliance marker and its metabolite concentration in the urine and the urine specific gravity adjusted to account for the difference between the urine measured specific gravity and a preselected reference urine specific gravity, (d) comparing the normalized urine compliance marker and its metabolite concentration with an expected normalized urine compliance marker and its metabolite concentration for the amount of compliance marker prescribed, as an indication of compliance or non-compliance.
Claim 6
Dependent Claim
50 words
The method of claim 3 further including the step: (e) calculating the amount of prescribed medication actually ingested by multiplying the prescribed medication dose with the calculated normalized urine compliance marker and its metabolite concentration, and dividing the product by the expected normalized urine compliance marker and its metabolite concentration.
Claim 7
Dependent Claim
94 words
The method of claim 3 wherein step (c) the normalized urine compliance marker and its metabolite concentration is calculated in accordance with the equation nu=u·SGF·(WGT/K) where nu is the normalized urine compliance marker and its metabolite concentration, u is the measured raw urine compliance marker and its metabolite concentration, SGF is the specific gravity factor of the urine sample calculated from the equation (rsg-1.000)/(msg-1.000), where rsg is the preselected reference urine specific gravity, and where msg is the urine measured specific gravity, where WGT is the patient body weight and K is a constant.
Claim 8
Dependent Claim
18 words
The method of claim 3 wherein step (b) the concentration of a benzodiazepine and its metabolites are measured.
Claim 9
Dependent Claim
10 words
The method of claim 6 wherein the benzodiazepine is diazepam.
Claim 10
Dependent Claim
10 words
The method of claim 6 wherein the benzodiazepine is alprazolam.
Claim 11
Dependent Claim
18 words
The method of claim 3 wherein step (b) the concentration of a barbiturate and its metabolites are measured.
Claim 12
Dependent Claim
10 words
The method of claim 9 wherein the barbiturate is phenobarbital.
Claim 13
Independent Claim
131 words
A method of monitoring compliance of a patient who has been placed on a medication maintenance program with a prescribed medication dosage and having a compliance marker physically associated with the medication at a predetermined dosage, and with the method comprising the steps of: (a) obtaining a sample of the patient's urine, (b) measuring the concentration of the compliance marker and its metabolites in the urine and the urine osmolality, (c) calculating a normalized urine compliance marker and its metabolite concentration as a function of the measured compliance marker concentration and its metabolite in the urine and the urine osmolality, (d) comparing the normalized urine compliance marker and its metabolite concentration with an expected normalized urine compliance marker and its metabolite concentration value prescribed, as an indication of compliance or non-compliance.
Claim 14
Independent Claim
131 words
A method of monitoring compliance of a patient who has been placed on a medication maintenance program with a prescribed medication dosage and having a compliance marker physically associated with the medication at a predetermined dosage, and with the method comprising the steps of: (a) obtaining a sample of the patient's urine, (b) measuring the concentration of the compliance marker and its metabolites in the urine and the urine osmolality, (c) calculating a normalized urine compliance marker and its metabolite concentration as a function of the measured compliance marker concentration and its metabolite in the urine and the urine osmolality, (d) comparing the normalized urine compliance marker and its metabolite concentration with an expected normalized urine compliance marker and its metabolite concentration value prescribed, as an indication of compliance or non-compliance.
Claim 15
Dependent Claim
50 words
The method of claim 11 further including the step: (e) calculating the amount of prescribed medication actually ingested by multiplying the prescribed medication dose with the calculated normalized urine compliance marker and its metabolite concentration, and dividing the product by the expected normalized urine compliance marker and its metabolite concentration.
Claim 16
Dependent Claim
99 words
The method of claim 11 wherein step (c) the normalized urine compliance marker and its metabolite concentration is calculated in accordance with the equation nu=u·UOF·(WGT/K) where nu is the normalized urine compliance marker and its metabolite concentration, u is the measured raw urine compliance marker and its metabolite concentration, UOF is the urine osmolality factor of the urine sample defined as the ratio of the urine osmolality at a specific gravity of a reference urine sample to the urine osmolality equivalent at the actual urine specific gravity, where WGT is the patient body weight and K is a constant.
Claim 17
Dependent Claim
18 words
The method of claim 11 wherein step (b) the concentration of a benzodiazepine and its metabolites are measured.
Claim 18
Dependent Claim
10 words
The method of claim 14 wherein the benzodiazepine is diazepam.
Claim 19
Dependent Claim
10 words
The method of claim 14 wherein the benzodiazepine is alprazolam.
Claim 20
Dependent Claim
20 words
The method of claim 11 wherein step (b) the concentration of a barbiturate compliance marker and its metabolites are measured.
Claim 21
Dependent Claim
10 words
The method of claim 17 wherein the barbiturate is phenobarbital.
Claim 22
Dependent Claim
20 words
A method of claim 3 wherein step (b) the concentration of a weakly acidic medication and its metabolites are measured.
Claim 23
Dependent Claim
20 words
A method of claim 11 wherein step (b) the concentration of a weakly acidic medication and its metabolites are measured.
References Cited (Backward Citations)
US2564247A
Cited
US3856469A
Cited
US3901655A
Cited
US4104367A
Cited
US4196185A
Cited
US5047329A
Cited
US5137692A
Cited
US5179027A
Cited
US5547878A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-07-06 | 2002-01-05 | 2002-07-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-07-06 | 2006-01-05 | 2006-07-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-07-06 | 2010-01-05 | 2010-07-07 | $7700.00 | Window Closed / Lapsed |